Afraxis Raises $1.2M in Venture Funding

5/14/10

San Diego-based aFraxis, which has completed pre-clinical testing of a promising compound for treating fragile X syndrome, the most common cause of inherited mental impairment, has raised $1.2 million in a venture round targeting $6 million, according to a recent regulatory finding. San Diego’s Avalon Ventures already has invested about $6 million since the company was founded three years ago.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.